Travis J Moss1, Matthew M Zipse2, Mori J Krantz2,3, William H Sauer2, Ernesto E Salcedo2, Joseph L Schuller2,3. 1. Division of Cardiovascular Medicine, University of Virginia School of Medicine, Charlottesville, VA. 2. Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO. 3. Cardiovascular Division, Denver Health Medical Center, Denver, CO.
Abstract
BACKGROUND: Patients with hypertrophic cardiomyopathy (HCM) are at a fourfold to sixfold higher risk of developing atrial fibrillation (AF) compared to the general population, though incidence rates among patients undergoing alcohol septal ablation (ASA) are not well characterized. The purpose of this study was to evaluate atrial fibrillation incidence following ASA. METHODS: We studied 132 consecutive HCM patients without comorbid AF that underwent 154 ASA procedures. The incidence of AF in follow-up was assessed through chart abstraction including electrocardiography. Survival free of AF was estimated using Kaplan-Meier methodology. RESULTS: Over a mean follow-up of 3.6 ± 2.7 years (maximum 11.3 years), 10 (7.6%) patients developed new-onset AF. Of those who developed AF, both resting and provoked left ventricular outflow tract (LVOT) gradients had improved significantly (difference -79.78 mm Hg, P ≤ 0.005). Severity of mitral regurgitation improved in 7 (70%) patients. Survival free of AF was estimated to be 99.1%, 93.7%, and 91.7% at 1, 3, and 5 years. CONCLUSIONS: Despite relieving LVOT obstruction and improving mitral regurgitation severity via ASA, new-onset AF remained a common complication of hypertrophic cardiomyopathy.
BACKGROUND:Patients with hypertrophic cardiomyopathy (HCM) are at a fourfold to sixfold higher risk of developing atrial fibrillation (AF) compared to the general population, though incidence rates among patients undergoing alcohol septal ablation (ASA) are not well characterized. The purpose of this study was to evaluate atrial fibrillation incidence following ASA. METHODS: We studied 132 consecutive HCM patients without comorbid AF that underwent 154 ASA procedures. The incidence of AF in follow-up was assessed through chart abstraction including electrocardiography. Survival free of AF was estimated using Kaplan-Meier methodology. RESULTS: Over a mean follow-up of 3.6 ± 2.7 years (maximum 11.3 years), 10 (7.6%) patients developed new-onset AF. Of those who developed AF, both resting and provoked left ventricular outflow tract (LVOT) gradients had improved significantly (difference -79.78 mm Hg, P ≤ 0.005). Severity of mitral regurgitation improved in 7 (70%) patients. Survival free of AF was estimated to be 99.1%, 93.7%, and 91.7% at 1, 3, and 5 years. CONCLUSIONS: Despite relieving LVOT obstruction and improving mitral regurgitation severity via ASA, new-onset AF remained a common complication of hypertrophic cardiomyopathy.
Authors: C Briguori; S Betocchi; M A Losi; F Manganelli; F Piscione; L Pace; M Boccalatte; R Gottilla; M Salvatore; M Chiariello Journal: Am J Cardiol Date: 1998-01-15 Impact factor: 2.778
Authors: F Airoldi; C Di Mario; A Catanoso; A Dharmadhikari; V Tzifos; A Anzuini; M Carlino; C Briguori; M Montorfano; M Vaghetti; S Tolaro; A Colombo Journal: Ital Heart J Date: 2000-03
Authors: Daniel Monakier; Anna Woo; Timothy Puri; Leonard Schwartz; John Ross; Michal Jamorski; Hua Yang; Zheng Liu; Mani Vannan; E Douglas Wigle; Harry Rakowski Journal: Am J Cardiol Date: 2004-12-15 Impact factor: 2.778
Authors: Morten Kvistholm Jensen; Vibeke Marie Almaas; Linda Jacobsson; Peter Riis Hansen; Ole Havndrup; Svend Aakhus; Bertil Svane; Thomas Fritz Hansen; Lars Køber; Knut Endresen; Maria J Eriksson; Erik Jørgensen; Jan Peder Amlie; Fredrik Gadler; Henning Bundgaard Journal: Circ Cardiovasc Interv Date: 2011-05-03 Impact factor: 6.546
Authors: Paul Sorajja; Uma Valeti; Rick A Nishimura; Steve R Ommen; Charanjit S Rihal; Bernard J Gersh; David O Hodge; Hartzell V Schaff; David R Holmes Journal: Circulation Date: 2008-07-08 Impact factor: 29.690
Authors: Mariusz Klopotowski; Aleksandra Kwapiszewska; Krzysztof Kukula; Jacek Jamiolkowski; Maciej Dabrowski; Pawel Derejko; Artur Oreziak; Rafal Baranowski; Mateusz Spiewak; Magdalena Marczak; Anna Klisiewicz; Barbara Szepietowska; Zbigniew Chmielak; Adam Witkowski Journal: Clin Cardiol Date: 2018-10-16 Impact factor: 2.882
Authors: Travis J Moss; Matthew M Zipse; Mori J Krantz; William H Sauer; Ernesto E Salcedo; Joseph L Schuller Journal: Ann Noninvasive Electrocardiol Date: 2016-03-11 Impact factor: 1.468
Authors: Mihaela Octavia Popa; Ana Maria Irimia; Mihai Nicolae Papagheorghe; Elena Miruna Vasile; Simona Andreea Tircol; Raluca Andreea Negulescu; Catalina Toader; Robert Adam; Lucian Dorobantu; Cristina Caldararu; Maria Alexandrescu; Sebastian Onciul Journal: Discoveries (Craiova) Date: 2016-06-30